Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 25.03.2024 2 Abdom Radiol (NY) 1 Ann Med 2 Arch Ital Urol Androl 2 BJU Int 1 BMC Immunol 2 BMC Urol 1 Br J Cancer 1 Cancer Epidemiol 1 Cell Mol Biol Lett 1 Clin Pharmacol Ther 1 Comb Chem High Throughput Screen 1 Eur J Epidemiol 1 Eur Rev Med Pharmacol Sci 6 Eur Urol 2 Eur Urol Open Sci 1 Front Immunol 3 Front Oncol 1 Future Oncol 1 Gan To Kagaku Ryoho 3 Heliyon 1 Int Immunopharmacol 1 Int J Oncol 1 J Biomol Struct Dyn 1 J Cancer 2 J Cell Mol Med 1 J Egypt Natl Canc Inst 1 J Investig Med High Impact Case Rep 1 J Med Chem 1 J Pathol Clin Res 1 J Sex Med 1 J Transl Med 1 J Vet Med Sci 1 JCO Clin Cancer Inform 1 JCO Precis Oncol 1 Mol Biol Res Commun 1 Mol Cancer 1 Mol Carcinog 1 Nan Fang Yi Ke Da Xue Xue Bao 1 Nat Commun 1 Neoplasma 1 Noncoding RNA Res 1 Pathol Int 1 Pol Arch Intern Med 1 Sci Rep 1 Toxicology 1 Urol Int 1 Urol J 2 Urol Oncol 7 World J Urol 1 Zhonghua Zhong Liu Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. LIANG JP, Yin L, Gao LK, Yin L, et al
   Contrast-enhanced CT in the differential diagnosis of bladder cancer and paraganglioma.
   Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04217.
   PubMed         Abstract available
   
   
2. CHAI JL, Roller LA, Liu X, Lan Z, et al
   Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis.
   Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04245.
   PubMed         Abstract available
   
   

   
   Ann Med

3. SUN X, Liu C, Zhang C, Zhang Z, et al
   Nomogram for predicting postoperative ileus after radical cystectomy and urinary diversion: a retrospective single-center study.
   Ann Med. 2024;56:2329125.
   PubMed         Abstract available
   
   

   
   Arch Ital Urol Androl

4. LEONARDI R, Ambrosini F, Cafarelli A, Calarco A, et al
   Office-based management of non-muscle invasive bladder cancer (NMIBC): a position paper on current state of the art and future perspectives.
   Arch Ital Urol Androl. 2024 Mar 19:12404. doi: 10.4081/aiua.2024.12404.
   PubMed         Abstract available
   
   
5. MOUSSA M, Abou Chakra M, Shore ND, Papatsoris A, et al
   Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
   Arch Ital Urol Androl. 2024 Mar 19:12244. doi: 10.4081/aiua.2024.12244.
   PubMed         Abstract available
   
   

   
   BJU Int

6. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
   Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
   BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
   PubMed         Abstract available
   
   
7. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
   Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
   BJU Int. 2024;133:474-479.
   PubMed         Abstract available
   
   

   
   BMC Immunol

8. MOADAB A, Valizadeh MR, Nazari A, Khorramdelazad H, et al
   Association of interleukin-17A and chemokine/vascular endothelial growth factor-induced angiogenesis in newly diagnosed patients with bladder cancer.
   BMC Immunol. 2024;25:20.
   PubMed         Abstract available
   
   

   
   BMC Urol

9. YE J, Zheng L, Chen Z, Wang Q, et al
   Serum alpha-hydroxybutyrate dehydrogenase as a biomarker for predicting survival outcomes in patients with UTUC after radical nephroureterectomy.
   BMC Urol. 2024;24:62.
   PubMed         Abstract available
   
   
10. IKUMA S, Akatsuka J, Takeda H, Endo Y, et al
    Determining the clinicopathological significance of the VI-RADS >==4 group: a retrospective study.
    BMC Urol. 2024;24:63.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. JONES RJ, Crabb SJ, Linch M, Birtle AJ, et al
    Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
    Br J Cancer. 2024;130:897-907.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol

12. WU KY, Cheong IS, Lai JN, Hu CY, et al
    Risk of secondary primary malignancies in survivors of upper tract urothelial carcinoma: A nationwide population-based analysis.
    Cancer Epidemiol. 2024;89:102536.
    PubMed         Abstract available
    
    

    
    Cell Mol Biol Lett

13. LV L, Wei Q, Zhang J, Dong Y, et al
    IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
    Cell Mol Biol Lett. 2024;29:39.
    PubMed         Abstract available
    
    

    
    Clin Pharmacol Ther

14. DE CARLO A, Tosca EM, Fantozzi M, Magni P, et al
    Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma.
    Clin Pharmacol Ther. 2024;115:825-838.
    PubMed         Abstract available
    
    

    
    Comb Chem High Throughput Screen

15. LIU F, Li J, Zhou B, Shen Y, et al
    The Role of Emodin in the Treatment of Bladder Cancer based on Network Pharmacology and Experimental Verification.
    Comb Chem High Throughput Screen. 2024.
    PubMed         Abstract available
    
    

    
    Eur J Epidemiol

16. VAN DEN BRANDT PA
    Diabetes and the risk of bladder cancer subtypes in men and women: results from the Netherlands Cohort Study.
    Eur J Epidemiol. 2024 Mar 16. doi: 10.1007/s10654-024-01100.
    PubMed         Abstract available
    
    

    
    Eur Rev Med Pharmacol Sci

17. WANG JF, Gong YQ, He YH, Ying WW, et al
    Author Correction: High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer.
    Eur Rev Med Pharmacol Sci. 2024;28:1640.
    PubMed         Abstract available
    
    

    
    Eur Urol

18. COX A, Klumper N, Stein J, Sikic D, et al
    Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
    Eur Urol. 2024;85:328-332.
    PubMed         Abstract available
    
    
19. LIEDBERG F, Bobjer J
    Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
    Eur Urol. 2024;85:392.
    PubMed        
    
    
20. PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
    Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.
    Eur Urol. 2024;85:348-360.
    PubMed         Abstract available
    
    
21. DAHM P, Ergun O, Sathianathen N
    Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Contr
    Eur Urol. 2024;85:e116.
    PubMed        
    
    
22. LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
    The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
    Eur Urol. 2024;85:317-319.
    PubMed         Abstract available
    
    
23. ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
    Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
    Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    

    
    Eur Urol Open Sci

24. DE JONG FC, Ifle IG, van der Made AC, Kooper D, et al
    A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
    Eur Urol Open Sci. 2024;62:131-139.
    PubMed         Abstract available
    
    
25. HAN H, Oh TJ, Heo JE, Lee J, et al
    Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2024;62:99-106.
    PubMed         Abstract available
    
    

    
    Front Immunol

26. BERGMAN DR, Wang Y, Trujillo E, Fernald AA, et al
    Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
    Front Immunol. 2024;15:1358019.
    PubMed         Abstract available
    
    

    
    Front Oncol

27. CHEN Y, Shi K, Fu X, Guo H, et al
    Diagnostic and prognostic potential of exosome non-coding RNAs in bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2024;14:1336375.
    PubMed         Abstract available
    
    
28. PAVAN N, Scaggiante B
    Editorial: Liquid biopsy in the detection and prediction of outcomes in bladder cancer.
    Front Oncol. 2024;14:1391466.
    PubMed        
    
    
29. TAO T, Chen Y, Shang Y, He J, et al
    SMMF: a self-attention-based multi-parametric MRI feature fusion framework for the diagnosis of bladder cancer grading.
    Front Oncol. 2024;14:1337186.
    PubMed         Abstract available
    
    

    
    Future Oncol

30. CRITCHLOW S, Bullement A, Crabb S, Jones R, et al
    Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
    Future Oncol. 2024;20:459-470.
    PubMed         Abstract available
    
    

    
    Gan To Kagaku Ryoho

31. KOMORI K, Koyama K, Shimizu K, Kanemoto R, et al
    [A Case of Colon Metastasis after Surgery for Left Renal Pelvis Cancer].
    Gan To Kagaku Ryoho. 2024;51:340-342.
    PubMed         Abstract available
    
    

    
    Heliyon

32. WANG Y, Wang J, Liu Y, Wang X, et al
    Multidimensional pan-cancer analysis of HSPA5 and its validation in the prognostic value of bladder cancer.
    Heliyon. 2024;10:e27184.
    PubMed         Abstract available
    
    
33. DU G, Jiang Z, Qu W, Zhang J, et al
    Downstaging guided neoadjuvant strategy shift and bladder preservation in locally advanced bladder cancer: A case report.
    Heliyon. 2024;10:e27685.
    PubMed         Abstract available
    
    
34. WANG KY, Wang KJ, Shen LL, Wang XH, et al
    The down-regulation of GADD45B leads to a conversion of cellular oxidative phosphorylation to glycolysis and promotes the progression of bladder cancer.
    Heliyon. 2024;10:e27427.
    PubMed         Abstract available
    
    

    
    Int Immunopharmacol

35. WANG C, Yang X
    CircRAPGEF5 sponges miR-582-3p and targets KIF3A to regulate bladder cancer cell proliferation, migration and invasion.
    Int Immunopharmacol. 2024;131:111613.
    PubMed         Abstract available
    
    

    
    Int J Oncol

36. XU M, Gu M, Zhou J, Da J, et al
    [Retracted] Interaction of YAP1 and mTOR promotes bladder cancer progression.
    Int J Oncol. 2024;64:50.
    PubMed         Abstract available
    
    

    
    J Biomol Struct Dyn

37. WU H, Jin H, Cai Y
    Unveiling therapeutic prospects: targeting MDM-2 in non-muscle invasive bladder cancer.
    J Biomol Struct Dyn. 2024 Mar 18:1-10. doi: 10.1080/07391102.2024.2329799.
    PubMed         Abstract available
    
    

    
    J Cancer

38. YAO R, Ai B, Wang Z, Shen B, et al
    Uncovering Microbial Composition of the Tissue Microenvironment in Bladder Cancer using RNA Sequencing Data.
    J Cancer. 2024;15:2431-2441.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

39. WANG Y, Wang J, Zhang L, He J, et al
    Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target.
    J Cell Mol Med. 2024;28:1-20.
    PubMed         Abstract available
    
    
40. DONG C, Hui P, Wu Z, Li J, et al
    CircRNA LOC729852 promotes bladder cancer progression by regulating macrophage polarization and recruitment via the miR-769-5p/IL-10 axis.
    J Cell Mol Med. 2024;28:e18225.
    PubMed         Abstract available
    
    

    
    J Egypt Natl Canc Inst

41. LIU Y, Zhang K, Yang X
    CircMCTP2 enhances the progression of bladder cancer by regulating the miR-99a-5p/FZD8 axis.
    J Egypt Natl Canc Inst. 2024;36:8.
    PubMed         Abstract available
    
    

    
    J Investig Med High Impact Case Rep

42. ARABYAN G, Hambartzhumian R, Lim A, Quizon M, et al
    Unusual Urothelial Tumors and Refractory Uremia Due to Balkan Endemic Nephropathy: A Case Report.
    J Investig Med High Impact Case Rep. 2024;12:23247096241238529.
    PubMed         Abstract available
    
    

    
    J Med Chem

43. QIN X, Wang H, Xu W, Zheng B, et al
    A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer.
    J Med Chem. 2024 Mar 18. doi: 10.1021/acs.jmedchem.4c00060.
    PubMed         Abstract available
    
    

    
    J Pathol Clin Res

44. ANGELONI M, van Doeveren T, Lindner S, Volland P, et al
    A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
    J Pathol Clin Res. 2024;10:e12369.
    PubMed         Abstract available
    
    

    
    J Sex Med

45. CEASAR RC, Ladi-Seyedian SS, Escobar D, Han J, et al
    "I think my vagina is still there?": Women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study.
    J Sex Med. 2024 Mar 15:qdae025. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Transl Med

46. LI L, Jiang P, Hu W, Zou F, et al
    AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
    J Transl Med. 2024;22:295.
    PubMed         Abstract available
    
    

    
    J Vet Med Sci

47. YU TW, Yamamoto H, Morita S, Fukushima R, et al
    Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.
    J Vet Med Sci. 2024;86:317-321.
    PubMed         Abstract available
    
    

    
    JCO Clin Cancer Inform

48. EMINAGA O, Lee TJ, La V, Breil B, et al
    Electronic Documentation of Intraoperative Observation of Cystoscopic Procedures Using the cMDX Information System.
    JCO Clin Cancer Inform. 2024;8:e2300114.
    PubMed         Abstract available
    
    

    
    JCO Precis Oncol

49. KEHL KL, Lavery JA, Brown S, Fuchs H, et al
    Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set.
    JCO Precis Oncol. 2024;8:e2300489.
    PubMed         Abstract available
    
    

    
    Mol Biol Res Commun

50. TOUALA-CHAILA Z, Abderrahmane RK, Kerroumi S, Yousfi MJ, et al
    Association study of the polymorphisms rs2228611 of the DNMT1 gene and rs1569686 of the DNMT3B gene with bladder cancer development in a sample of the Algerian population.
    Mol Biol Res Commun. 2024;13:65-72.
    PubMed         Abstract available
    
    

    
    Mol Cancer

51. WU J, Lin Y, Yang K, Liu X, et al
    Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.
    Mol Cancer. 2024;23:57.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

52. WANG B, Fan X, Wang L, Wei X, et al
    The RNA-binding protein sorbin and SH3 domain-containing 2 are transcriptionally regulated by specificity protein 1 and function as tumor suppressors in bladder cancer by stabilizing tissue factor pathway inhibitor.
    Mol Carcinog. 2024 Mar 19. doi: 10.1002/mc.23717.
    PubMed         Abstract available
    
    

    
    Nan Fang Yi Ke Da Xue Xue Bao

53. CHEN S, Zhang S, Fan W, Sun W, et al
    [Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
    Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:210-216.
    PubMed         Abstract available
    
    

    
    Nat Commun

54. OHARA K, Rendeiro AF, Bhinder B, Eng KW, et al
    The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
    Nat Commun. 2024;15:2009.
    PubMed         Abstract available
    
    

    
    Neoplasma

55. YANG J, Xiang H, Cheng M, Jiang X, et al
    microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2.
    Neoplasma. 2024;71:60-69.
    PubMed         Abstract available
    
    

    
    Noncoding RNA Res

56. HASHEM M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, et al
    Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.
    Noncoding RNA Res. 2024;9:560-582.
    PubMed         Abstract available
    
    

    
    Pathol Int

57. KIMURA T, Okita Y, Nagumo Y, Chin JM, et al
    Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif.
    Pathol Int. 2024 Mar 19. doi: 10.1111/pin.13419.
    PubMed         Abstract available
    
    

    
    Pol Arch Intern Med

58. SKOWRONSKI M, Halicki P, Halicka A
    Disseminated BCGitis after intravesical Bacillus Calmette-Guerin therapy in a patient with bladder cancer.
    Pol Arch Intern Med. 2024 Mar 20:16710. doi: 10.20452/pamw.16710.
    PubMed        
    
    

    
    Sci Rep

59. MURAKAMI T, Minami K, Harabayashi T, Maruyama S, et al
    Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients.
    Sci Rep. 2024;14:6801.
    PubMed         Abstract available
    
    

    
    Toxicology

60. WU J, Gao F, Meng R, Li H, et al
    Single-cell and multi-omics analyses highlight cancer-associated fibroblasts-induced immune evasion and epithelial mesenchymal transition for smoking bladder cancer.
    Toxicology. 2024;504:153782.
    PubMed         Abstract available
    
    

    
    Urol Int

61. DUAN H, Deng Z, Zou J, Zhang G, et al
    The efficacy and safety of Hyperthermia intravesical chemotherapy in the treatment non-muscle invasive bladder cancer:A meta analysis.
    Urol Int. 2024 Mar 20. doi: 10.1159/000538373.
    PubMed         Abstract available
    
    

    
    Urol J

62. PAZIR Y, Esmeray A, Gelmis M, Caglar U, et al
    Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
    Urol J. 2024 Mar 17. doi: 10.22037/uj.v20i.7854.
    PubMed         Abstract available
    
    

    
    Urol Oncol

63. BENBASSAT J
    Estimates of the lead time in screening for bladder cancer.
    Urol Oncol. 2024;42:110-114.
    PubMed         Abstract available
    
    
64. CZECH AK, Gronostaj K, Frydrych J, Polok K, et al
    The assessment of bladder cancer resectability with bimanual palpation: A prospective study in laparoscopy and open cystectomy patients.
    Urol Oncol. 2024 Mar 19:S1078-1439(24)00335.
    PubMed         Abstract available
    
    

    
    World J Urol

65. NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
    Treatment patterns and prognosis in patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    World J Urol. 2024;42:185.
    PubMed         Abstract available
    
    
66. BAARD J, Cormio L, Dasgupta R, Maruzzi D, et al
    Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study.
    World J Urol. 2024;42:177.
    PubMed         Abstract available
    
    
67. KLEIN C, Brunelle S, Illy M, De Luca V, et al
    Multiparametric Magnetic Resonance Imaging in the follow-up of non-muscle-invasive bladder tumors after intravesical instillations: a promising tool.
    World J Urol. 2024;42:178.
    PubMed         Abstract available
    
    
68. ALHAJAHJEH A, Abdulelah AA, Hmeidan M, Kakish D, et al
    Gender inequality in genitourinary malignancies clinical trials leadership.
    World J Urol. 2024;42:174.
    PubMed         Abstract available
    
    
69. ROSENBAUM CM, Filmar S, Gross AJ, Jobst N, et al
    The influence of socioeconomic status and gender on incidence and survival in bladder cancer: a longitudinal study based on the Hamburg Cancer Registry.
    World J Urol. 2024;42:166.
    PubMed         Abstract available
    
    
70. SUARTZ CV, Cordeiro MD, Botelho LAA, Gallucci FP, et al
    Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score.
    World J Urol. 2024;42:155.
    PubMed         Abstract available
    
    
71. PYRGIDIS N, Schulz GB, Volz Y, Ebner B, et al
    The impact of perioperative risk factors on long-term survival after radical cystectomy: a prospective, high-volume cohort study.
    World J Urol. 2024;42:164.
    PubMed         Abstract available
    
    

    
    Zhonghua Zhong Liu Za Zhi

72. WEI T, Yuan P
    [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
    Zhonghua Zhong Liu Za Zhi. 2024;46:211-220.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.